Having raised an $18 million Series B, Nora is continuing a Phase II trial of lead G-CSF candidate NT100 in IVF failure. But the biotech also has begun enrolling a second Phase II study in women with unexplained recurrent miscarriage.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2014.

Having raised an $18 million Series B, Nora is continuing a Phase II trial of lead G-CSF candidate NT100 in IVF failure. But the biotech also has begun enrolling a second Phase II study in women with unexplained recurrent miscarriage.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.